罗欣药业:聘任武永生为公司财务负责人

Group 1 - The core point of the article is the resignation of Chen Xian as the financial head of Luoxin Pharmaceutical due to job relocation, and the appointment of Wu Yongsheng as the new financial head [1] - For the first half of 2025, Luoxin Pharmaceutical's revenue composition is as follows: pharmaceutical industry accounts for 88.11%, pharmaceutical commerce accounts for 10.1%, and other businesses account for 1.79% [1] - As of the report date, Luoxin Pharmaceutical has a market capitalization of 6.2 billion [1] Group 2 - The article also mentions similar appointments in other companies, such as the hiring of Zhang Ganlin as the financial head of Libet and Gu Li as the financial head of Xinyin Electronics [1] - Additionally, it notes the appointment of Bai Lin as the financial head of Lianrui New Materials [1]